On September 16, Johnson & Johnson JNJ announced plans to acquire Abbott Medical Optics for $4.325 billion in cash.
Credit Suisse’s Vamil Divan maintains a Neutral rating on Johnson & Johnson, with a price target of $123.
The Deal
The deal is expected to close in Q1:17, and Divan expects the acquisition to be immediately accretive to Johnson & Johnson’s non-GAAP EPS.
“While not transformative by any means given JNJ’s overall size and scale, we believe this deal is a good strategic fit within JNJ’s existing vision care business,” the analyst mentioned.
Given that the company has also undertaken deals in medical devices and consumer, Divan wondered whether management would now focus its attention of strengthening the pharmaceutical segment via business development.
Pricey Deal
While Abbott Medical Optics has three key business segments, including cataract surgery tools, refractive laser surgery tools and consumer eye health, Divan pointed out that Johnson & Johnson did not as yet have a presence in the vision surgical equipment field space, although the company did have expertise and scale in consumer vision brands and medical device manufacturing.
The analyst also noted that the price for the deal is higher than previous comparable deals by peers, while stating that the current deal could “create both revenue as well as COGS synergies through JNJ’s consumer brand equity, geographic footprint, as well as manufacturing scale.”
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.